Drugs / Bcl-Xl_42-CAF09b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03412786 | May 2018 → Dec 2021 | prostate cancer | Herlev Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bcl-Xl_42-CAF09b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03412786 ↗ |
| Action | Deplete | “vaccination with Bcl-XL-derived peptides can induce tumor-specific T cell responses that may lead to the elimination of cancer cells” PMID 36999039 ↗ Mar 2023 |
| Modality | Vaccine | “patients with hormone-sensitive prostate cancer (PC) received a vaccine consisting of Bcl-XL-peptide with CAF®09b as an adjuvant” PMID 36999039 ↗ Mar 2023 |
| Route | Intramuscular | “Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.” NCT03412786 ↗ |
| Route | Other | “Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.” NCT03412786 ↗ |